<h2>About Lecanemab Drug:</h2>

<ul>
	<li aria-level="1">Lecanemab is jointly developed by pharma companies Biogen and Eisai.</li>
	<li aria-level="1">Lecanemab belongs to a class of drugs called monoclonal antibodies. These antibody-mediated drugs target beta amyloid, the protein deposition that is seen in patients with Alzheimer&rsquo;s disease, and disrupts cells function.</li>
</ul>

&nbsp;

<h3>Alzheimer&rsquo;s disease</h3>

<ul>
	<li aria-level="1">It is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die.&nbsp; It involves parts of the brain that control thought, memory, and language.</li>
	<li aria-level="1">It can seriously affect a person&rsquo;s ability to carry out daily activities.</li>
</ul>

&nbsp;

<h3>India&rsquo;s scenario:</h3>

<ul>
	<li>
	In India, only 1 in 10 people with dementia receive any diagnosis, treatment or care for the disease, according to the World Alzheimer&rsquo;s Report, 2021. 
	</li>
</ul>

&nbsp;

<hr />
<h3>Q1)&nbsp;What are Monoclonal antibodies?</h3>

Monoclonal antibodies (mAb or moAb) are identical <a href="https://www.genscript.com/antibody-basics.html" style="text-decoration:none">immunoglobulins</a>, generated from a single B-cell clone which recognize unique epitopes, or binding sites, on a single antigen.

Source:&nbsp;<a href="https://www.thehindu.com/sci-tech/health/explained-will-new-drug-slow-progress-of-alzheimers/article66248705.ece%20%E2%80%98" style="text-decoration:none">The Hindu</a>

What is Lecanemab?

Overview:

The drug, Lecanemab, was recently tested on patients with early Alzheimer.

About Lecanemab Drug:

Alzheimer’s disease

India’s scenario:

Q1) What are Monoclonal antibodies?

What is Lecanemab?

Overview:

The drug, Lecanemab, was recently tested on patients with early Alzheimer.

About Lecanemab Drug:

Alzheimer’s disease

India’s scenario:

Q1) What are Monoclonal antibodies?

Download PDF

Share this article